Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Hochfellner, DA; Rainer, R; Ziko, H; Aberer, F; Simic, A; Lichtenegger, KM; Beck, P; Donsa, K; Pieber, TR; Fruhwald, FM; Rosenkranz, AR; Kamolz, LP; Baumann, PM; Mader, JK; Plank, J.
Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis.
Diabetes Obes Metab. 2021; 23(9):2161-2169
Doi: 10.1111/dom.14458
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Hochfellner Daniel
- Mader Julia
- Co-authors Med Uni Graz
- Aberer Felix
- Baumann Petra Martina
- Fruhwald Friedrich
- Kamolz Lars-Peter
- Lichtenegger Katharina
- Pieber Thomas
- Rosenkranz Alexander
- Simic Amra
- Ziko Haris
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIM: To evaluate the efficacy and safety of basal-bolus insulin therapy in managing glycaemia during fasting periods in hospitalized patients with type 2 diabetes. MATERIALS AND METHODS: We performed a post hoc analysis of two prospective, uncontrolled interventional trials that applied electronic decision support system-guided basal-bolus (meal-related and correction) insulin therapy. We searched for fasting periods (invasive or diagnostic procedures, medical condition) during inpatient stays. In a mixed model analysis, patients' glucose levels and insulin doses on days with regular food intake were compared with days with fasting periods. RESULTS: Out of 249 patients, 115 patients (33.9% female, age 68.3 ± 10.3 years, diabetes duration 15.1 ± 10.9 years, body mass index 30.1 ± 5.4 kg/m2 , HbA1c 69 ± 20 mmol/mol) had 194 days with fasting periods. Mean daily blood glucose (BG) was lower (modelled difference [ModDiff]: -0.5 ± 0.2 mmol/L, P = .006), and the proportion of glucose values within the target range (3.9-10.0 mmol/L) increased on days with fasting periods compared with days with regular food intake (ModDiff: +0.06 ± 0.02, P = .005). Glycaemic control on fasting days was driven by a reduction in daily bolus insulin doses (ModDiff: -11.0 ± 0.9 IU, P < .001), while basal insulin was similar (ModDiff: -1.1 ± 0.6 IU, P = .082) compared with non-fasting days. Regarding hypoglycaemic events (BG < 3.9 mmol/L), there was no difference between fasting and non-fasting days (χ2 0.9% vs. 1.7%, P = .174). CONCLUSIONS: When using well-titrated basal-bolus insulin therapy in hospitalized patients with type 2 diabetes, the basal insulin dose does not require adjustment during fasting periods to achieve safe glycaemic control, provided meal-related bolus insulin is omitted and correction bolus insulin is tailored to glucose levels.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Blood Glucose - administration & dosage
- Diabetes Mellitus, Type 2 - drug therapy
- Fasting - administration & dosage
- Female - administration & dosage
- Glycated Hemoglobin A - analysis
- Glycemic Control - administration & dosage
- Humans - administration & dosage
- Hypoglycemic Agents - administration & dosage
- Insulin - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prospective Studies - administration & dosage
- Find related publications in this database (Keywords)
- basal insulin
- clinical trial
- continuous glucose monitoring (CGM)
- insulin therapy
- type 2 diabetes